Special Issue

Genomic Alterations in Leukemia (Volume II)

Message from the Guest Editor

Acute leukemias, specifically acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), are influenced by genetic alterations that have significant clinical, prognostic, and therapeutic implications. Detecting these alterations and their associated transcriptional signatures is essential for diagnosis, risk assessment, and treatment. The complexity of leukemic cells, along with the expansion of resistant clones, can contribute to disease persistence or recurrence. Single-cell technologies have provided insights into clonal heterogeneity, cell developmental state composition, and interactions with the microenvironment, advancing our understanding of acute leukemia pathogenesis and treatment response. This Special Issue will showcase the latest advancements in ALL and AML research, including genetic discoveries, faithful cellular and in vivo models, and computational analysis methods. It aims to improve the analysis of acute leukemia at both bulk and single-cell resolution, enhance clinical management, and refine therapeutic approaches.

Guest Editor

Dr. Ilaria Iacobucci

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

Deadline for manuscript submissions

closed (31 December 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/195282

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)